According to this Medscape overview,

Investigators conducted a post hoc analysis of data collected from a total of 3188 people with type 2 diabetes who had been adherent to their assigned Tirzepatide regimen for 40–42 weeks in any one of four pivotal trials of the agent: SURPASS-1, SURPASS-2, SURPASS-3, and SURPASS-4.

• Higher Tirzepatide dose
• Being female
• Being of White or Asian race
• Being of younger age
• Undergoing treatment with metformin
• Having better glycemic control (based on lower A1c and lower fasting serum glucose)
• Having lower non-high-density lipoprotein (non-HDL) cholesterol level.

Do these factors describe you?